"With this collaboration, Pfizer, Hadassah Medical Organization, The Hebrew University of Jerusalem and the JDRF are creating a unique model for how clinical and biomedical scientists in industry and academia, in collaboration with non-profit organizations, can work together for the benefit of patients." said Tim Rolph, PhD., Vice President of Pfizer's Cardiovascular Metabolic and Endocrine Diseases Research. "Each group brings to the table its specific set of skills and expertise to address complex problems that each alone would take much longer to solve."

"We are very excited about this program and the close collaboration with JDRF and Pfizer," said Dr. Dor. "Ben Glaser and myself have put considerable efforts in recent years into understanding the basic mechanisms by which the total number of beta cells in healthy adult organisms is regulated, and what triggers the formation of new beta cells when demand exceeds supply. With this new project we are given a chance to examine if our insights can be utilized, using clinically relevant drugs supplied by Pfizer, for boosting beta cell mass in healthy and diabetic mice."

Source: Juvenile Diabetes Research Foundation International